NIH awards $12M for development of antiviral therapies

By The Science Advisory Board staff writers

November 22, 2022 -- The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), has awarded three institutions more than $12 million for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.

The new product development contracts are part of the Antiviral Program for Pandemics (APP), which aims to accelerate the discovery, development, and manufacturing of antiviral medicines.

The following are the awardees:

  • Microbiotix for "Optimization of Broad-Spectrum Filovirus Inhibitors that Target Viral Glycoprotein"
  • Oregon Health and Science University for "Development of a Novel 2-Pyrimidone (SRI-42718) as a Potent Inhibitor of Chikungunya Virus Infection and Disease"
  • Baruch S. Blumberg Institute for "Development of an Orally Available Antiviral Drug for Yellow Fever"

The institutions will develop promising antiviral candidates from late-stage preclinical studies to investigational new drug application-enabling activities and clinical testing.

For more information about the APP, please visit the program's webpage.

Copyright © 2022

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.